[PDF][PDF] Right in time: Mitapivat for the treatment of anemia in α-and β-thalassemia
KM Musallam, AT Taher, MD Cappellini - Cell Reports Medicine, 2022 - cell.com
KM Musallam, AT Taher, MD Cappellini
Cell Reports Medicine, 2022•cell.comKuo and colleagues 1 evaluated the safety and efficacy of mitapivat, an oral pyruvate kinase
activator, in adults with non-transfusion-dependent α-thalassemia or β-thalassemia. The
high rate of hemoglobin response and good tolerability encourages further development in
thalassemia.
activator, in adults with non-transfusion-dependent α-thalassemia or β-thalassemia. The
high rate of hemoglobin response and good tolerability encourages further development in
thalassemia.
Kuo and colleagues1 evaluated the safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion-dependent α-thalassemia or β-thalassemia. The high rate of hemoglobin response and good tolerability encourages further development in thalassemia.
cell.com